Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Keeps R&D Focus, Spins Out Phase II Neuromyelitis Optica MAb Into New Biotech

Executive Summary

Six early-stage biologics with potential to treat inflammation and auto-immunity disorders have been spun out of AstraZeneca's biologics arm, MedImmune, into a stand-alone Chinese investor-backed company, Viela Bio, underlining the commitment of the big pharma to its three areas of therapeutic focus.

Advertisement

Related Content

Viela Adds Momentum To Burgeoning NMOSD Market With Pivotal Inebilizumab Results
AZ Cashes In On No-Longer Core Nexium
Chugai May Not Win Race For $500m Neuromyelitis Optica Market, But May Best Soliris On Ease Of Use
Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline
AstraZeneca's Pipeline Reaps Rewards Of Return To Science

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100475

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel